ELCC 2017 | Data update in advanced stage NSCLC
Solange Peters, MD, PhD, from the University of Lausanne, Lausanne, Switzerland discusses the ongoing clinical trials investigating advanced stage non-small cell lung cancer (NSCLC) at the annual meeting of the European Lung Cancer Conference (ELCC) 2017, Geneva, Switzerland. Dr Peters provides insight into the design of the ETOP 6-14 NICOLAS trial (NCT02434081), investigating the addition of the anti-PD-1 agent, nivolumab, to standard first-line chemotherapy and radiotherapy. Making comparisons to the PACIFIC (NCT02125461) trial, evaluating the anti-PD-L1 agent, durvalumab following concurrent chemoradiation therapy, Dr Peters shares the latest results from both trials.
Get great new content delivered to your inboxSign up